Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGX-4010 (Qutenza) in Postherpetic Neuralgia (Study C110)
NCT00068081Phase 3Completed
- Sponsor
- NeurogesX
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of capsaicin 8% patch in postherpetic neuralgia (PHN) (2 arms), sponsored by NeurogesX. Primary endpoint: Percentage change in Numeric Pain Rating Scale score. Status: completed.
02
Drugs
capsaicin 8% patch
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT00068081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068081.